185 related articles for article (PubMed ID: 19362945)
1. Updated clinical information on multitargeted antifolates in lung cancer.
Scagliotti GV; Ceppi P; Capelletto E; Novello S
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S35-40. PubMed ID: 19362945
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
3. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
4. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
[TBL] [Abstract][Full Text] [Related]
5. [Pemetrexed: from preclinic to clinic].
Lansiaux A; Lokiec F
Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed for the treatment of non-small-cell lung cancer.
Manegold C; Schmid-Bindert G; Pilz LR
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
Solomon B; Bunn PA
Future Oncol; 2005 Dec; 1(6):733-46. PubMed ID: 16556051
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Adjei AA
Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
[TBL] [Abstract][Full Text] [Related]
11. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.
Bosch-Barrera J; Gaztañaga M; Ceballos J; Pérez-Gracia JL; López-Picazo JM; García-Foncillas J; Ferrer M; Sanz ML; Pretel M; Idoate MA; Gil-Bazo I
Onkologie; 2009 Oct; 32(10):580-4. PubMed ID: 19816075
[TBL] [Abstract][Full Text] [Related]
12. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
13. [Update of pemetrexed in thoracic oncology].
Brechot JM; Morère JF
Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
[TBL] [Abstract][Full Text] [Related]
14. [A brief overview of a lung cancer biomarker: thymidylate synthase].
Rouquette I; Mazieres J
Rev Mal Respir; 2011 Jun; 28(6):773-7. PubMed ID: 21742238
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
16. [Pemetrexed].
Sudoh J; Gemma A
Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
[TBL] [Abstract][Full Text] [Related]
17. [Second-line treatment of advanced non-small-cell lung cancer: role of pemetrexed].
Pérol M
Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S14-7. PubMed ID: 16273004
[No Abstract] [Full Text] [Related]
18. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
20. Review of a promising new agent--pemetrexed disodium.
Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
